These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
25. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P; Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544 [TBL] [Abstract][Full Text] [Related]
26. Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. Verschuur CV; Suwijn SR; Post B; Dijkgraaf M; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Deuschl G; Lang AE; de Haan RJ; de Bie RM BMC Neurol; 2015 Nov; 15():236. PubMed ID: 26584951 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109 [TBL] [Abstract][Full Text] [Related]
28. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S; Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014 [TBL] [Abstract][Full Text] [Related]
29. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191 [TBL] [Abstract][Full Text] [Related]
30. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
31. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
32. Ropinirole: a review of its use in the management of Parkinson's disease. Matheson AJ; Spencer CM Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932 [TBL] [Abstract][Full Text] [Related]
33. Deferasirox for managing iron overload in people with thalassaemia. Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446 [TBL] [Abstract][Full Text] [Related]
34. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880 [TBL] [Abstract][Full Text] [Related]
36. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics. Yoritaka A; Abe T; Ohtsuka C; Maeda T; Hirayama M; Watanabe H; Saiki H; Oyama G; Fukae J; Shimo Y; Hatano T; Kawajiri S; Okuma Y; Machida Y; Miwa H; Suzuki C; Kazama A; Tomiyama M; Kihara T; Hirasawa M; Shimura H; Hattori N BMC Neurol; 2016 May; 16():66. PubMed ID: 27176725 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. Simuni T; Fiske B; Merchant K; Coffey CS; Klingner E; Caspell-Garcia C; Lafontant DE; Matthews H; Wyse RK; Brundin P; Simon DK; Schwarzschild M; Weiner D; Adams J; Venuto C; Dawson TM; Baker L; Kostrzebski M; Ward T; Rafaloff G; JAMA Neurol; 2021 Mar; 78(3):312-320. PubMed ID: 33315105 [TBL] [Abstract][Full Text] [Related]
38. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766 [TBL] [Abstract][Full Text] [Related]
39. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546 [TBL] [Abstract][Full Text] [Related]
40. Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms. Sun Y; Pham AN; Waite TD ACS Chem Neurosci; 2018 May; 9(5):1118-1127. PubMed ID: 29381045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]